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Abstract 
Laropiprant (LRPT) is being developed in combination with Merck's extended-release niacin 
(ERN) formulation for the treatment of dyslipidemia. LRPT, an antagonist of the prostaglandin 
PGD2 receptor DP1, reduces flushing symptoms associated with ERN. LRPT also has affinity for 
the thromboxane A2 receptor TP (approximately 190-fold less potent at TP compared with DP1). 
Aspirin and clopidogrel are two frequently used anti-clotting agents with different mechanisms 
of action. Since LRPT may potentially be co-administered with either one of these agents, these 
studies were conducted to assess the effects of steady-state LRPT on the antiplatelet activity of 
steady-state clopidogrel or aspirin. Bleeding time at 24 hr postdose (trough) was prespecified as 
the primary pharmacodynamic endpoint in both studies. Two, separate, double-blind, 
randomized, placebo-controlled, crossover studies evaluated the effects of multiple-dose LRPT 
on the pharmacodynamics of multiple-dose clopidogrel or aspirin. Healthy subjects were 
randomized to once-daily oral doses of LRPT 40 mg or placebo to LRTP co-administered with 
clopidogrel 75 mg or aspirin 81 mg for 7 days with at least a 21-day washout between treatments. 
In both studies, bleeding time and platelet aggregation were assessed 4 and 24 hours post-dose 
on Day 7. Comparability was declared if the 90% confidence interval for the estimated geometric 
mean ratio ([LRPT + clopidogrel]/clopidogrel alone or [LRPT + aspirin]/aspirin alone) for 
bleeding time at 24 hours post-dose on Day 7 was contained within (0.66, 1.50). Concomitant 
daily administration of LRPT 40 mg with clopidogrel 75 mg or aspirin 81 mg resulted in an 
approximate 4% to 5% increase in bleeding time at 24 hours after the last dose vs. bleeding time 
after treatment with clopidogrel or aspirin alone, demonstrating that the treatments had 
comparable effects on bleeding time. Percent inhibition of platelet aggregation was not 
significantly different between LRPT co-administered with clopidogrel or aspirin vs clopidogrel 
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or aspirin alone at 24 hours postdose at steady state. At 4 hours after the last dose, co-
administration of LRPT 40 mg resulted in 3% and 41% increase in bleeding time vs bleeding 
time after treatment with aspirin or clopidogrel alone, respectively. Co-administration of LPRT 
with clopidogrel or aspirin was generally well tolerated in healthy subjects. Co-administration of 
multiple doses of LRPT 40 mg and clopidogrel 75 mg or aspirin 81 mg had no clinically 
important effects on bleeding time or platelet aggregation.  
 
Key words: Clopidogrel, aspirin, laropiprant, pharmacokinetics 
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Introduction 
Niacin, at gram doses, has broad beneficial effects on the overall plasma lipoprotein profile (i.e., 
increases high-density lipoprotein cholesterol and lowers low-density lipoprotein cholesterol, 
triglycerides, and lipoprotein (a) levels) and improves cardiovascular outcomes when 
administered alone or in combination with other lipid-altering agents [1-4]. Niacin is 
underutilized in clinical practice for the treatment of dyslipidemia primarily due to the 
bothersome side effect of flushing, which limits niacin dose escalation and frequently leads to 
the discontinuation of therapy [5-8].  
Niacin-induced flushing is mediated primarily by prostaglandin D2 (PGD2), which 
activates PGD2 receptor-1 (DP1) in the skin [9-15]. Laropiprant (LRPT) is an orally active, 
potent, highly selective antagonist of DP1 that has been shown to be effective in suppressing 
niacin-induced flushing when co-administered with extended-release niacin (ERN) [16-19]. In 
patients with dyslipidemia, co-administration of LRPT with ERN reduced both the incidence and 
intensity of niacin-induced flushing symptoms without diminishing the lipid-altering benefits of 
niacin therapy [20,21]. The concomitant administration of LRPT and ERN has the potential to 
significantly improve the tolerability and optimize therapeutic dosing of niacin, thereby 
improving the clinical effectiveness of niacin therapy. 
In vitro studies have demonstrated that PGD2 inhibits platelet aggregation and that 
activated platelets release PGD2. Thus, antagonism of DP1 by LRPT has been postulated to 
inhibit the activity of platelet-derived PGD2, thereby indirectly enhancing the reactivity of 
platelets. Activated platelets release thromboxane A2 (TxA2), which, acting through its receptor 
TxA2/prostaglandin H2 (TP), promotes platelet aggregation. LRPT also has antagonist affinity for 
the receptor TP, although it is 190-fold less potent at TP compared with DP1. In contrast to the 
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uncertain role of DP1 in regulating platelet function, the importance of TP and the thromboxane 
pathway in modulating platelet function has been clearly established [22]. Taken together, these 
data suggest that LRPT may have the potential to alter platelet function, either by enhancing 
platelet reactivity through DP1 antagonism or by inhibiting platelet aggregation through TP 
antagonism. The overall clinical significance of LRPT interactions with receptors DP1 and TP 
has been assessed with several different assays using both ex vivo and in vivo methods. A recent 
study demonstrated that LRPT administered alone or in combination with ERN does not enhance 
platelet reactivity as assessed by collagen-induced platelet aggregation and bleeding time in 
healthy subjects [23].  
Aspirin and clopidogrel are two commonly used antiplatelet agents with different 
mechanisms of action [21,24]. Since LRPT may potentially be co-administered with either one of 
these agents, clinical studies were conducted to assess the effects of steady-state LRPT on the 
antiplatelet activity of steady-state clopidogrel or aspirin. This paper describes the results of two, 
separate, double-blind, randomized, placebo-controlled, crossover studies designed to evaluate 
the effects of multiple therapeutic doses of LRPT on the antiplatelet activity of multiple-dose 
aspirin or clopidogrel as measured by bleeding time and platelet aggregation in healthy subjects. 
 
Methods 
Patient Selection Criteria 
Both studies enrolled healthy, non-smoking men and women judged to be in good general health 
based on medical history, physical examination, and laboratory testing. The first (Merck & Co., 
Inc., Phase I, Protocol No. 049) and second (Merck & Co., Inc., Phase I, Protocol No. 072) 
studies enrolled subjects 18 to 45 or 18 to 55 years, respectively. Subjects were excluded from 
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study participation if they had a history of major gastrointestinal abnormalities or disease, peptic 
ulceration, hematologic, immunologic, genitourinary, cardiovascular, hepatic, renal, pulmonary, 
psychiatric, or metabolic/endocrine disease. Subjects were not permitted to use aspirin, NSAIDS, 
or prescription or non-prescription medications or consume excessive amounts of alcohol or 
caffeinated beverages during the conduct of either study. Protocol 072 specified that subjects 
with clopidogrel resistance i.e. clopidogrel non-responders (<10% change from baseline platelet 
aggregation induced by ADP in Treatment B at 4 hours postdose on Day 7) would have been 
excluded from the primary efficacy analysis, but no subjects met this criterion. 
Each subject signed a written informed consent before any study procedures or 
examinations were performed. The study was conducted in accordance with principles of Good 
Clinical Practice and was approved by the appropriate institutional review boards and regulatory 
agencies.  
 
Study Designs 
Two separate, double-blind, randomized, placebo-controlled, crossover studies were 
conducted to evaluate the effects of multiple dose LRPT on the antiplatelet effects of multiple-
dose aspirin (Aspirin Study; Protocol No. 049) and clopidogrel (Clopidogrel Study; Protocol No. 
072). Within each study, eligible subjects were randomized to a sequence of two treatments 
(Treatments A and B) and each subject received both treatments in crossover fashion, therefore 
acting as their own control. The order in which subjects received each treatment was randomly 
assigned by a computer-generated allocation schedule, and there was a minimum 21-day 
washout between each treatment period.  
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In the Aspirin Study, eligible subjects were randomized to receive aspirin 81 mg co-
administered with LRPT 40 mg once daily for 7 days (Treatment A) and aspirin 81 mg co-
administered with placebo once daily for 7 days (Treatment B) in a cross-over fashion. In this 
study, study medication was administered at approximately the same time each day. Doses on 
Days 1, 5, 6, and 7 were administered under supervision in the research unit with approximately 
240 mL of water following an overnight fast. Doses on Days 2 to 4 were self administered by the 
subjects outside the clinical research unit. On Day 7 of both treatment periods, water intake was 
restricted 1 hour prior to and after the administration of study drug. On Day 7 of both treatment 
periods, a standard meal was provided after the completion of study procedures.   
In the Clopidogrel Study, eligible subjects were randomized to receive clopidogrel 75 mg 
co-administered with LRPT 40 mg once-daily for 7 days (Treatment A) and clopidogrel 75 mg 
co-administered with placebo once daily for 7 days  (Treatment B) in a cross-over fashion. In 
this study, all doses of study medication were administered with 240 mL of water immediately 
following the ingestion of a standard low-fat breakfast. On Day 7 of both treatment periods, 
subjects fasted for 4 hours after dosing. A standard meal was provided after the completion of 
study procedures on Days 7 and 8.   
In both studies, LRPT 40 mg (3 × 5-mg and 1 × 25-mg tablets; Merck & Co., Inc, 
Rahway, NJ) and placebo (placebo for LRPT 3 × 5-mg and 1 × 25-mg tablets; Merck & Co., Inc, 
Rahway, NJ) were administered in a double-blind manner according to a randomized allocation 
schedule, while aspirin 81 mg (1 × 81 mg tablet; Children's Chewable Tablets, Bayer HealthCare 
LLC, in Leverkusen, Germany) or clopidogrel 75 mg (1 × 75 mg tablet; Plavix® tablets; Bristol-
Myers Squibb/Sanofi Pharmaceuticals Partnership, Bridgewater, NJ) were administered open 
label.  
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Pharmacodynamic Assessments 
Bleeding time measurements were obtained prestudy, 4 hours postdose on Day 7 and 24 hours 
postdose on day 7. A small incision wound was made with a disposable bleeding-time device 
(Surgicutt®; International Technidyne Corporation, Edison, NJ). The time of the incision and the 
time at which bleeding from the incision stopped were recorded. Bleeding times in the Aspirin 
study greater than 20 minutes and greater than 30 minutes in the Clopidogrel study were 
truncated and the measurement was reported as >1200 seconds or >1800 seconds, respectively.  
 The pharmacodynamic goals of both studies were to determine the effect of multiple-dose 
LRPT 40 mg on bleeding time and platelet aggregation in the presence of either aspirin or 
clopidogrel over a 24-hour period after dosing on Day 7. To assess the effects of LRPT on 
platelet aggregation, blood samples (15 mL) were collected at prestudy, predose on Day 1, 4 
hours postdose on Day 7, and 24 hours postdose on Day 7. Blood samples were collected into 
buffered 0.106 M sodium citrate tubes and centrifuged at 400×g for 10 minutes at room 
temperature to harvest platelet-rich plasma (PRP). The remaining volume was centrifuged at 
1500×g for 10 minutes to obtain platelet-poor plasma (PPP). The platelet count of the PRP was 
adjusted to approximately 200,000 to 300,000 platelets/µL by dilution with PPP. Aliquots of 
0.45 mL adjusted for PRP or PPP were added to separate aggregometer cuvettes and warmed to 
37°C. The cuvettes were placed in separate wells, with the PPP serving as a blank for light 
transmission. Once the baseline was stabilized, the aggregometer (2-channel) (Chronolog, 
Havertown, PA) was calibrated and the increases in light transmission were measured following 
the addition of 2 µg/mL collagen as the primary agonist. In the Clopidogrel Study 5.0 µM ADP 
(4 hours and 24 hours postdose on Day 7) also was used as an agonist. All platelet aggregation 
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studies were performed within 1.5 hours of the blood collection. Aggregation was followed for 5 
minutes after the addition of agonist and the maximum percentage of light transmission (i.e., 
extent of transmission, primary variable) obtained during this period and the instrument-
calculated slope (i.e., rate of aggregation, secondary variable) was recorded.  
 
Safety Measurements 
Safety and tolerability were assessed by clinical evaluation of adverse events (AEs) and 
inspection of safety parameters, including physical examinations, vital signs, routine laboratory 
safety measurements (hematology, blood chemistry, and urinalysis), and 12-lead 
electrocardiograms (12-lead ECG). AEs were monitored throughout the study and evaluated in 
terms of intensity (mild, moderate, severe), duration, severity, outcome, and relationship to study 
drug. 
 
Statistical Analyses 
A mixed-effects model appropriate for a 2-period, crossover study design with terms for 
sequence, period, treatment as fixed effects and subject within sequence as a random effect was 
used to evaluate the effect of LRPT on aspirin- or clopidogrel-induced bleeding time. Bleeding 
time data were analyzed on the log scale, and the data were back transformed for reporting 
purposes. Ninety percent confidence intervals (CIs) were calculated for the geometric mean ratio 
(GMR, [LRPT+aspirin]/aspirin or [LRPT+clopidogrel]/clopidogrel) of bleeding time of [aspirin 
+ LRPT] or [clopidogrel + LRPT] vs. aspirin or clopidogrel alone at 24 hours post-dose on Day 
7 and compared with the prespecified similarity bounds of (0.66, 1.50). If the 90% CI fell within 
(0.66, 1.50), it would be concluded that the effects of [aspirin + LRPT] or [clopidogrel + LRPT] 
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on bleeding time were similar to aspirin or clopidogrel alone at 24 hours postdose on Day 7 (i.e., 
primary endpoint). Similar analyses were repeated for bleeding time at 4 hours postdose on Day 
7 (i.e., exploratory endpoint). In the case of any censored values on bleeding time, the truncated 
bleeding times were estimated by the maximum observed bleeding time (i.e., 1200 seconds in 
the Aspirin Study and 1800 seconds in the Clopidogrel Study).  
The effects of LRPT on the percent inhibition of platelet aggregation induced by various 
agonists (i.e., 2 µg/mL collagen [in both studies], 5.0 µM ADP [in the Clopidogrel Study in the 
presence of aspirin or clopidogrel at 4 hours and 24 hours postdose on Day 7) was analyzed 
using the same mixed effect model described for the bleeding time analyses. The baseline 
measurement was defined as the predose measurement performed on Day 1. Percent inhibition 
of platelet aggregation was calculated as a 1 minus percentage change from the baseline of the 
extent of platelet aggregation. The analysis was performed on the log scale and final results 
were reported on the original scale following back-transformation. SAS version 8.2 (SAS 
Institute, Cary, NC, USA) was used for all statistical analyses.  
 
Results 
In the Aspirin study, 14 healthy subjects were enrolled and randomized to treatment (Table I). 
All 14 subjects completed the study per protocol and were included in the pharmacodynamic 
and safety analyses. In the Clopidogrel study, 22 subjects were enrolled and randomized to 
treatment (Table I). Twenty-one subjects completed the study per protocol and were included in 
the pharmacodynamic analyses. One subject discontinued from the study due to increased 
hepatic enzyme levels (see further details in safety and tolerability section). All 21 subjects were 
included in the safety analyses.  
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Bleeding Times 
The estimated GMRs (90% CIs) for bleeding time measured in the Aspirin and Clopidogrel 
Studies are shown in Table II.  
 In the Aspirin Study, the mean bleeding time profiles following concomitant 
administration of (aspirin + LRPT) or aspirin alone for 7 days are shown in Figure 1. The 
bleeding time profiles for the two treatments were generally superimposable across the prestudy, 
4 hour, and 24 hour postdose time points. The GMRs ([LRPT + aspirin]/aspirin) and 
corresponding 90% CIs for the GMRs of bleeding times for [aspirin + LRPT] vs. aspirin alone 
at 4 (i.e., exploratory endpoint) and 24 hours (i.e., primary endpoint) postdose on Day 7 were 
1.03 (0.86, 1.22) and 1.05 (0.93, 1.19), respectively. The 90% CIs for these GMRs fell entirely 
within the prespecified clinical similarity bounds of (0.67, 1.50). Furthermore, there were no 
statistically significant differences (p>0.200) in bleeding times between [aspirin + LRPT] and 
aspirin alone at 4 and 24 hours postdose on Day 7. These findings support the conclusion that 
the bleeding time observed following concomitant administration of aspirin 81 mg and LRPT 40 
mg for 7 days was similar to that following the administration of aspirin 81 mg alone for 7 days.  
In the Clopidogrel study, the mean bleeding time profiles following concomitant 
administration of [clopidogrel + LRPT] or clopidogrel alone for 7 days are shown in Figure 2. 
The bleeding time profiles for the two treatments were generally superimposable across the 
prestudy and 24-hour postdose time points but not the 4-hour postdose time point. The GMR 
([LRPT+clopidogrel]/clopidogrel) 90% CI for the GMR of bleeding time for [clopidogrel + 
LRPT] vs. clopidogrel alone at 24 hours (i.e., primary endpoint) postdose on Day 7 was 1.04 
(0.80, 1.34) which fell entirely within the prespecified clinical similarity bounds of (0.67, 1.50) 
  13 
 
(Table II). The GMR and 90% CI for bleeding time at 4 hours (i.e., exploratory endpoint) 
postdose on Day 7 was 1.41 (1.09, 1.83). A statistically significant increase (p = 0.028) in 
bleeding time was seen with [clopidogrel + LRPT] vs. clopidogrel alone at 4 hours postdose on 
Day 7, whereas no significant between-treatment difference was seen at 24 hours postdose. 
These findings support the conclusion that bleeding time at 24 hours postdose on Day 7 
following concomitant administration of clopidogrel 75 mg and LRPT 40 mg was similar to that 
seen following the administration of clopidogrel 75 mg alone for 7 days; however, a transient 
increase in bleeding time was observed following treatment with [clopidogrel + LRPT] at 4 
hours postdose.   
 
Platelet Aggregation 
The effects of LRPT on platelet aggregation induced by various agonists (i.e., 2 µg/mL collagen 
[in both studies], 5.0 µM ADP [in the Clopidogrel Study], in the presence of aspirin or 
clopidogrel at 4 hours and 24 hours postdose on Day 7 are summarized in Tables III and IV, 
respectively. The time profile plots of percent inhibition of platelet aggregation as measured by 
percent amplitude in the Aspirin and Clopidogrel studies are depicted in Figures 3 and 4, 
respectively.  
In the Aspirin Study, no statistically significant differences in collagen-induced platelet 
aggregation were seen at 4 and 24 hours postdose on Day 7 following treatment with [aspirin + 
LRPT] vs. aspirin alone (p=0.362 and p=0.987, respectively) (Table III). The time profile plots 
of percent inhibition in platelet aggregation were generally superimposable across the predose 
on Day 1, and 4 hour and 24 hour postdose time points (Figure 3). In the Clopidogrel Study, the 
percent inhibition in platelet aggregation induced by collagen and ADP were not statistically 
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significantly different (p>0.050) following treatment with [clopidogrel + LRPT] vs. clopidogrel 
alone at 24 hours postdose on Day 7 (Table IV). At 4 hours postdose on Day 7, statistically 
significant between-treatment differences (p<0.050) in the percent inhibition of collagen and 
ADP-induced platelet aggregation were observed (Table IV). Specifically, treatment with 
[clopidogrel + LRPT] vs. LRPT alone led to increases in inhibition of collagen- and ADP-
induced platelet aggregation by 25% and 7%, respectively, at 4 hours postdose on Day 7 
(Figure 4).   
 
Safety and Tolerability 
Co-administration of multiple-dose aspirin 81 mg or clopidogrel 75 mg with multiple-dose 
LRPT 40 mg was generally well-tolerated in healthy adult subjects. No serious clinical or 
serious laboratory adverse experiences were reported in either study and there were no 
consistent treatment-related changes in laboratory, 12-lead electrocardiogram or vital sign safety 
parameters.  
In the Aspirin study, 5 subjects reported a total of 12 clinical adverse experiences of 
which 9 (i.e., nausea, loose stools, fatigue, abdominal cramp, general body pain, throat irritation, 
dry throat, scalp laceration and ecchymosis) occurred in subjects receiving [aspirin + LRPT] and 
3 (i.e., cough, nasal congestion, rhinitis) occurred in subjects receiving aspirin alone. All of 
these adverse experiences were considered by the investigator to be mild in intensity, did not 
require action regarding study drugs, and all experiences resolved by the end of the study. One 
subject reported 1 adverse experience (i.e., abdominal cramp) while receiving [aspirin + LRPT], 
which was considered by the investigator to be possibly drug-related. There were no laboratory 
adverse experiences in this study.  
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In the Clopidogrel study, 16 subjects reported a total of 34 clinical adverse experiences 
of which 20 occurred in subjects receiving [clopidogrel + LRPT] and 14 occurred in subjects 
receiving clopidogrel alone (Table V). The most common clinical adverse experiences reported 
were headache, abdominal discomfort, nausea and vomiting. Two subjects experienced 
laboratory adverse experiences of white blood cells in urine while taking [clopidogrel + LRPT] 
which the investigator considered definitely not related to study drug. One subject was 
discontinued from the study prior to dosing [placebo + LRPT] on Day 2 of Period 1 due to 
increased hepatic enzyme levels already present prior to dosing. The investigator did not 
consider this discontinuation to be related to an adverse experience or to be drug related because 
the elevated enzyme was present before the study drug was administered. All 21 subjects were 
included in the safety analyses.  
 
Discussion 
The primary objectives of these studies were to evaluate the effects of LRPT, administered at the 
therapeutic dose of 40 mg, on the anti-platelet activity of aspirin or clopidogrel as measured by 
bleeding time and platelet responsiveness to inducers of platelet aggregation (i.e., collagen and 
ADP). Aspirin and clopidogrel are widely used antiplatelet drugs that lower morbidity and 
mortality in patients with cardiovascular risk [25]. Because many patients with dyslipidemia take 
aspirin and a significant number also take clopidogrel to reduce the risk of atherothrombotic 
events, these studies were performed to investigate the potential pharmacodynamic interaction 
between LRPT and either aspirin or clopidogrel.  
Bleeding time at 24 hr postdose (trough) was prespecified as the primary 
pharmacodynamic endpoint in both studies. When properly conducted, capillary bleeding time is 
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considered a reproducible and sensitive method to measure the effects of treatment on overall 
hemostasis [26]. The bleeding time assesses platelet function in the context of damaged skin and 
microvasculature as well as the interaction of platelets with the coagulation and fibrinolytic 
system. Ex vivo platelet aggregometry assays also were conducted in both studies in an 
exploratory manner to evaluate platelet reactivity in response to inducers of platelet aggregation 
(i.e., agonists) in platelet rich plasma. Collagen was used as an agonist in both studies to induce 
the aggregation of platelets ex vivo. Aspirin inhibits collagen-induced platelet aggregation by 
blocking TxA2 synthesis and preventing the activation of TP [21]. For the Clopidogrel study, 
ADP also was used as an agonist because clopidogrel inhibits platelet aggregation by inhibiting 
the binding of ADP to its platelet receptor and the subsequent ADP-mediated activation of the 
glycoprotein complex governing platelet adhesion to the substratum [27]. Clopidogrel also 
suppresses platelet aggregation induced by agonists other than ADP by inhibiting the 
amplification of platelet activation by released ADP [28]. 
The co-administration of LRPT 40 mg and aspirin 81 mg for 7 days did not alter the 
known effects of aspirin on the prolongation bleeding time or inhibition of collagen-induced 
platelet aggregation compared with aspirin alone. At 24 hours post dose on Day 7, there were 
neither clinically meaningful nor statistically significant changes in bleeding time or platelet 
aggregation with [aspirin + LRPT] vs. aspirin alone. Similar findings were also observed at 4 
hours postdose on Day 7. These findings indicate that LRPT neither reduces nor enhances the 
antiplatelet activity of aspirin in healthy adult subjects. The dose of aspirin used in this study was 
expected to suppress COX-1 derived prostanoids from platelets, including TxA2 and PDG2, but 
not from other cellular sources. The lack of an effect of LRPT on the antiplatelet effects of 
aspirin was not surprising given that the activities of these two drugs are believed to be mediated 
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by a common pathway. Aspirin 81 mg has been shown to inhibit production of TxA2 by >95% 
which prevents the activation of the TP receptor and thus would be expected to abrogate modest 
inhibitory effects of LRPT on TP. 
The co-administration of LRPT 40 mg and clopidogrel 75 mg for 7 days resulted in 
modestly longer bleeding times and greater inhibition of collagen-induced platelet aggregation 
compared with clopidogrel alone at 4 hours post dose. These transient effects likely reflect the 
off-target activity of LRPT on the TP receptor. Inhibition of ADP-induced platelet aggregation 
also was significantly increased at 4 hours postdose but to a lesser degree compared with 
collagen. This finding was not surprising given that ADP-induced platelet aggregation is known 
to be less dependent on TP activation compared with that seen in response to collagen. At 24 
hours post dose on Day 7, there were no clinically meaningful or statistically significant changes 
in bleeding time or platelet aggregation with [clopidogrel + LRPT] vs. clopidogrel alone. Aspirin 
is effective in reducing the incidence of atherothrombotic events at doses that inhibit collagen-
induced platelet aggregation and prolong bleeding time throughout the entire dosing interval. 
Other NSAIDs that are reversible inhibitors of COX-1 and transiently inhibit platelet function 
have generally not been demonstrated to be effective at reducing atherothrombotic events. Based 
on these findings in the literature, it is concluded that transient effects on platelets which do not 
result in prolongation of bleeding time throughout the dosing interval are not likely to be 
clinically important. Taken together, these findings suggest that LRPT produces a transient, 
moderate, effect on the antiplatelet activity of clopidogrel at 4 hours postdose but did not result 
in any clinically important effects at the 24 hours postdose time point.  
The co-administration of LRPT 40 mg with either aspirin 81 mg or clopidogrel 75 mg 
was generally well tolerated in healthy adult subjects. There were no serious clinical or 
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laboratory adverse experiences reported in these studies. No subjects discontinued from these 
studies due to adverse experiences.. There were no clinically significant effects of the 
concomitant administration of LRPT and aspirin or clopidogrel on blood chemistry tests, 
hematology parameters, vital signs and ECG parameters. Overall, clinical adverse experiences 
associated with the concomitant administration of LRPT with aspirin or clopidogrel were mild, 
transient, and self-limited in nature.  
Acetylsalicylic acid (ASA) and clopidogrel are used together in patients with increased 
cardiovascular risk. The effect of LRPT in patients taking both antiplatelet agents cannot be 
determined from the results reported here. Studies evaluating the effect of LRPT on the 
antiplatelet activity of ASA and clopidogrel taken together will inform about the use of LRPT in 
these patients. Pending these results, clinicians should be aware of the potential increased 
antiplatelet effect of ASA and clopidogrel in combination with LRPT. 
 
Conclusion 
In summary, co-administration of multiple doses of LRPT 40 mg and aspirin 81 mg or 
clopidogrel 75 mg had no clinically relevant effects on bleeding time or platelet aggregation.  
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Table I. Baseline demographics for the randomized subjects 
 
Demographic Aspirin Study 
PN047 
Clopidogrel Study 
PN072 
Race, n (%) 
   Black 
   Hispanic 
   Caucasian 
 
6 (42.9%) 
1 (7.1%) 
7 (50.0%) 
 
0 
0 
22 (100%) 
Gender, n (%) 
   Male 
   Female 
 
10 (71.4%) 
4 (28.6%) 
 
12 (54.5%) 
10 (45.5%) 
Age (yr), mean (range) 31.1 (20-45) 37.0 (21-53) 
Height (cm), mean (range) 172.8 (151-190) 174.4 (159-189) 
Weight (kg), mean, (range) 77.3 (59.9-74.3) 74.6 (54.0-101.8) 
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Table II. Bleeding time (seconds) at 4 and 24 hours postdose on Day 7 following treatment with 
aspirin 81 mg or clopidogrel 75 mg with or without laropiprant 40 mg in healthy subjects 
 
Aspirin 
Aspirin+ 
Laropiprant [Aspirin+ Laropiprant]/Aspirin Time (Day 7) 
N LS meana N LS meana GMRb (90% CI) p-Value 
4 hr 14 572 14 587 1.03 (0.86, 1.22) 0.790 
24 hr 14 519 14 546 1.05 (0.93, 1.19) 0.461 
Clopidogrel 
Clopidogrel + 
Laropiprant 
(Clopidogrel + 
Laropiprant)/Clopidogrel) Time (Day 7) 
N LS meana N LS meana GMRc (90% CI) p-Value 
4 hr 20 622 20 879 1.41 (1.09, 1.83) 0.028 
24 hr 20 572 20 594 1.04 (0.80, 1.34) 0.803 
aLS mean = least squares mean; back-transformed from log scale 
bGMR = geometric least-squares mean ratio [aspirin + laropiprant]/aspirin  
cGMR = geometric least-squares mean ratio [clopidogrel + laropiprant]/clopidogrel 
CI = confidence interval 
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Table III. Summary statistics for percent inhibition of collagen-induced platelet aggregation at 4 
and 24 hours postdose on Day 7 following treatment with aspirin 81 mg with or without 
laropiprant 40 mg in healthy subjects 
 
% Inhibition of Platelet Aggregation Induced by Collagen (% Amplitude) 
Aspirin Aspirin + 
Laropiprant 
[Aspirin + Laropiprant]-Aspirin 
N Time (Day 7) 
LS meana Difference (90%CI) p-value 
14 4 hr 86.0 84.1 -1.9 (-5.5, 1.6) 0.362 
14 24 hr 81.3 81.2 -0.1 (-7.2, 7.1) 0.987 
aLS mean = least squares mean; back-transformed from log scale 
CI = confidence interval 
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Table IV. Summary statistics for percent inhibition of collagen- and ADP-induced platelet 
aggregation at 4 and 24 hours postdose on Day 7 following treatment with clopidogrel 75 mg 
with or without laropiprant 40 mg in healthy subjects 
 
 
LS Meana Differenceb (90% CI) p-value 
N Time (Day 7) Clopidogrel Clopidogrel + 
Laropiprant  
[Clopidogrel + Laropiprant] - 
 Clopidogrel 
% Inhibition of Platelet Aggregation Induced by Collagen: % Amplitude 
20 4 hr 14.2 38.9 24.6 (11.8, 37.6) 0.002 
20 24 hr 13.4 28.9 15.4 (1.7, 29.3) 0.065 
% Inhibition of Platelet Aggregation Induced by ADP: % Amplitude 
20 Day 7 - 4 hr 59.8 66.7 6.9 (2.9, 10.9) 0.005 
20 Day 7 - 24 hr 56.1 60.3 4.2 (-0.3, 8.7)  0.119 
aLS mean = least-squares mean; back-transformed from log scale 
bDifference = difference of percent inhibition between [clopidogrel + laropiprant] - clopidogrel 
back-transformed from log percent scale 
CI = confidence interval 
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Table V. Number (%) of subjects with specific clinical adverse experiences 
Placebo + Clopidogrel 
75 mg 
Laropiprant 40 mg + 
Clopidogrel 75 mg 
N = 21 N = 22 Adverse Experiences 
n (%)a n (%)a 
Gastrointestinal Disorders 
Abdominal discomfort 
Abdominal pain 
Diarrhea 
Dyspepsia 
Nausea 
Stomach discomfort 
Vomiting 
3 (14.3) 
1 (4.8) 
0 (0.0) 
1 (4.8) 
0 (0.0) 
0 (0.0) 
2 (9.5) 
1 (4.8) 
 
4 (18.2) 
0 (0.0) 
1 (4.5) 
1 (4.5) 
1 (4.5) 
1 (4.5) 
0 (0.0) 
1 (4.5) 
General Disorders/Treatment Site 
Conditions 
Fatigue 
Sensation of pressure 
Vessel puncture site hematoma 
Vessel puncture site pain 
 
1 (4.8) 
1 (4.8) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
 
 
2 (9.1) 
0 (0.0) 
1 (4.5) 
1 (4.5) 
1 (4.5) 
 
Infections and Infestations 
Influenza 
Nasopharyngitis 
1 (4.8) 
0 (0.0) 
1 (4.8) 
 
2 (9.1) 
1 (4.5) 
1 (4.5) 
Nervous System Disorders 
Headache 
4 (19.0) 
4 (19.0) 
 
3 (13.6) 
3 (13.6) 
Respiratory, Thoracic, and 
Mediastinal Disorders 
Cough 
Pharyngolaryngeal pain 
Rhinorrhea 
 
1 (4.8) 
1 (4.8) 
0 (0.0) 
1 (4.8) 
 
 
2 (9.1) 
0 (0.0) 
2 (9.1) 
0 (0.0) 
Skin and Subcutaneous Tissue 
Disorders 
Rash papular 
 
1 (4.8) 
1 (4.8) 
 
0 (0.0) 
0 (0.0) 
aAlthough a subject may have had two or more clinical adverse experiences, the subject is 
counted only once within a category. The same subject may appear in more than one category. 
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Figure Legends 
 
Figure 1. Time profile (mean ± SE) of bleeding time at 4 and 24 hours postdose on Day 7 
following treatment with aspirin 81 mg (Study 1) with or without laropiprant 40 mg.  
 
Figure 2. Time profile (mean ± SE) of bleeding time at 4 and 24 hours postdose on Day 7 
following treatment with clopidogrel 75 mg (Study 2) with or without laropiprant 40 mg.  
 
Figure 3. Time profile (mean ± SE) of percent inhibition from baseline in collagen-induced 
platelet aggregation at 4 and 24 hours postdose on Day 7 following treatment with aspirin 81 mg 
(Study 1) with or without laropiprant 40 mg.  
 
Figure 4. Time profile (mean ± SE) of percent inhibition from baseline in collagen- and ADP-
induced platelet aggregation at 4 and 24 hours postdose on Day 7 following treatment with 
clopidogrel 75 mg (Study 2) with or without laropiprant 40 mg.  
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